FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282923726> ?p ?o ?g. }

• W4282923726 endingPage "156" @default.
• W4282923726 startingPage "146" @default.
• W4282923726 abstract "Olutasidenib (FT-2102) is a highly potent, orally bioavailable, brain-penetrant and selective inhibitor of mutant isocitrate dehydrogenase 1 (IDH1). The aim of the study was to determine the safety and clinical activity of olutasidenib in patients with relapsed/refractory gliomas harboring an IDH1R132X mutation.This was an open-label, multicenter, nonrandomized, phase Ib/II clinical trial. Eligible patients (≥18 years) had histologically confirmed IDH1R132X-mutated glioma that relapsed or progressed on or following standard therapy and had measurable disease. Patients received olutasidenib, 150 mg orally twice daily (BID) in continuous 28-day cycles. The primary endpoints were dose-limiting toxicities (DLTs) (cycle 1) and safety in phase I and objective response rate using the Modified Response Assessment in Neuro-Oncology criteria in phase II.Twenty-six patients were enrolled and followed for a median 15.1 months (7.3‒19.4). No DLTs were observed in the single-agent glioma cohort and the pharmacokinetic relationship supported olutasidenib 150 mg BID as the recommended phase II dose. In the response-evaluable population, disease control rate (objective response plus stable disease) was 48%. Two (8%) patients demonstrated a best response of partial response and eight (32%) had stable disease for at least 4 months. Grade 3‒4 adverse events (≥10%) included alanine aminotransferase increased and aspartate aminotransferase increased (three [12%], each).Olutasidenib 150 mg BID was well tolerated in patients with relapsed/refractory gliomas harboring an IDH1R132X mutation and demonstrated preliminary evidence of clinical activity in this heavily pretreated population." @default.
• W4282923726 created "2022-06-16" @default.
• W4282923726 creator A5004217317 @default.
• W4282923726 creator A5010378038 @default.
• W4282923726 creator A5010759705 @default.
• W4282923726 creator A5013453936 @default.
• W4282923726 creator A5019278396 @default.
• W4282923726 creator A5026869480 @default.
• W4282923726 creator A5029013179 @default.
• W4282923726 creator A5034322764 @default.
• W4282923726 creator A5040373927 @default.
• W4282923726 creator A5042954440 @default.
• W4282923726 creator A5047608444 @default.
• W4282923726 creator A5056266073 @default.
• W4282923726 creator A5066471470 @default.
• W4282923726 creator A5072953400 @default.
• W4282923726 creator A5074549728 @default.
• W4282923726 creator A5089777560 @default.
• W4282923726 creator A5091098703 @default.
• W4282923726 creator A5091751573 @default.
• W4282923726 date "2022-05-25" @default.
• W4282923726 modified "2023-10-17" @default.
• W4282923726 title "Olutasidenib (FT-2102) in patients with relapsed or refractory <i>IDH1</i>-mutant glioma: A multicenter, open-label, phase Ib/II trial" @default.
• W4282923726 cites W1858161324 @default.
• W4282923726 cites W1967381518 @default.
• W4282923726 cites W1978853965 @default.
• W4282923726 cites W1980174217 @default.
• W4282923726 cites W1993605227 @default.
• W4282923726 cites W2054092941 @default.
• W4282923726 cites W2080452140 @default.
• W4282923726 cites W2109816625 @default.
• W4282923726 cites W2110794271 @default.
• W4282923726 cites W2124951199 @default.
• W4282923726 cites W2126817554 @default.
• W4282923726 cites W2131860315 @default.
• W4282923726 cites W2147387301 @default.
• W4282923726 cites W2154313451 @default.
• W4282923726 cites W2257254975 @default.
• W4282923726 cites W2476911293 @default.
• W4282923726 cites W2577801124 @default.
• W4282923726 cites W2793046629 @default.
• W4282923726 cites W2800469107 @default.
• W4282923726 cites W2801958156 @default.
• W4282923726 cites W2884741638 @default.
• W4282923726 cites W2890773484 @default.
• W4282923726 cites W2897143766 @default.
• W4282923726 cites W2912845066 @default.
• W4282923726 cites W2937257297 @default.
• W4282923726 cites W2952280304 @default.
• W4282923726 cites W2989871594 @default.
• W4282923726 cites W2991111955 @default.
• W4282923726 cites W2995984012 @default.
• W4282923726 cites W3001216252 @default.
• W4282923726 cites W3034266209 @default.
• W4282923726 cites W3091889888 @default.
• W4282923726 cites W3129779330 @default.
• W4282923726 cites W3136829774 @default.
• W4282923726 cites W3164133956 @default.
• W4282923726 cites W3166806880 @default.
• W4282923726 cites W3211790423 @default.
• W4282923726 doi "https://doi.org/10.1093/neuonc/noac139" @default.
• W4282923726 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35639513" @default.
• W4282923726 hasPublicationYear "2022" @default.
• W4282923726 type Work @default.
• W4282923726 citedByCount "16" @default.
• W4282923726 countsByYear W42829237262022 @default.
• W4282923726 countsByYear W42829237262023 @default.
• W4282923726 crossrefType "journal-article" @default.
• W4282923726 hasAuthorship W4282923726A5004217317 @default.
• W4282923726 hasAuthorship W4282923726A5010378038 @default.
• W4282923726 hasAuthorship W4282923726A5010759705 @default.
• W4282923726 hasAuthorship W4282923726A5013453936 @default.
• W4282923726 hasAuthorship W4282923726A5019278396 @default.
• W4282923726 hasAuthorship W4282923726A5026869480 @default.
• W4282923726 hasAuthorship W4282923726A5029013179 @default.
• W4282923726 hasAuthorship W4282923726A5034322764 @default.
• W4282923726 hasAuthorship W4282923726A5040373927 @default.
• W4282923726 hasAuthorship W4282923726A5042954440 @default.
• W4282923726 hasAuthorship W4282923726A5047608444 @default.
• W4282923726 hasAuthorship W4282923726A5056266073 @default.
• W4282923726 hasAuthorship W4282923726A5066471470 @default.
• W4282923726 hasAuthorship W4282923726A5072953400 @default.
• W4282923726 hasAuthorship W4282923726A5074549728 @default.
• W4282923726 hasAuthorship W4282923726A5089777560 @default.
• W4282923726 hasAuthorship W4282923726A5091098703 @default.
• W4282923726 hasAuthorship W4282923726A5091751573 @default.
• W4282923726 hasBestOaLocation W42829237261 @default.
• W4282923726 hasConcept C126322002 @default.
• W4282923726 hasConcept C142424586 @default.
• W4282923726 hasConcept C143998085 @default.
• W4282923726 hasConcept C181199279 @default.
• W4282923726 hasConcept C197934379 @default.
• W4282923726 hasConcept C2777150147 @default.
• W4282923726 hasConcept C2778227246 @default.
• W4282923726 hasConcept C2908647359 @default.
• W4282923726 hasConcept C31760486 @default.
• W4282923726 hasConcept C502942594 @default.
• W4282923726 hasConcept C535046627 @default.

• next